Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

By The ASCO Post Staff Posted: 2/3/2023 12:22:00 PM Last Updated: 2/3/2023 12:39:23 PM On February 3, the U.S. Food and Drug Administration (FDA)...

The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer...

Over the past 20 years, advances in genomic characterization of breast cancer enabled the constant evolution of clinically relevant subtypes from immunohistochemically defined groups,...

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...

Stephanie A. Berg, DO, discussed the implications of these findings on the urothelial cancer treatment paradigm and how updated results may further influence the...

Join the first European onco-urology event, UROonco23 in Gothenburg, Sweden from June 30 to July 2, 2023. Get updates on genitourinary (GU) cancers from...

2023 ASCO Gastrointestinal Cancers Symposium Filippo Pietrantonio, MD, of Italy’s Istituto Nazionale dei Tumori, discusses phase II results from the INFINITY trial of tremelimumab...

Neoadjuvant pembrolizumab was found to have high clinical activity and an acceptable safety profile in patients with localized microsatellite instability–high/deficient mismatch repair solid...

Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic...

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations,...